MACK Merrimack Pharmaceuticals Inc.

11.88
-0.30  -2%
Previous Close 12.18
Open 12.25
Price To book 1.42
Market Cap 158395648
Shares 13,332,967
Volume 61,640
Short Ratio 7.94
Av. Daily Volume 225,370

SEC filingsSee all SEC filings

  1. 8-K - Current report 171193175
  2. SC TO-I/A [Amend] - Tender offer statement by Issuer 171193163
  3. SC TO-I/A [Amend] - Tender offer statement by Issuer 171185806
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171185697
  5. 8-K - Current report 171185098

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation due 2017.
MM-121
HER2 negative metastatic breast cancer
Phase 2 completion of enrollment announced June 19, 2017. Data due 1H 2018.
MM-141 - CARRIE
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
ONIVYDE
Cancer - second line pancreatic
Phase 2 initiated mid Feb 2015. Data due 2H 2018.
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
ONIVYDE
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
ONIVYDE
Cancer - front line pancreatic

Latest News

  1. With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Inc’s (MACK) Management Done A Good Job?
  2. Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
  3. Edited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMT
  4. Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
  5. Merrimack beats 3Q profit forecasts
  6. Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss
  7. Merrimack Reports Third Quarter 2017 Financial Results
  8. Merrimack Pharmaceuticals, Inc. to Host Earnings Call
  9. What's in the Cards for Merrimack (MACK) in Q3 Earnings?
  10. Featured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer
  11. Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call
  12. Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121
  13. NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers
  14. Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer
  15. Have Investors Already Priced In Merrimack Pharmaceuticals Inc’s (MACK) Growth?
  16. Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020
  17. Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio?
  18. Merrimack Announces Settlement of Convertible Note Litigation
  19. Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)?
  20. Today's Research Reports on Trending Tickers: American Superconductor and Merrimack Pharmaceuticals

SEC Filings

  1. 8-K - Current report 171193175
  2. SC TO-I/A [Amend] - Tender offer statement by Issuer 171193163
  3. SC TO-I/A [Amend] - Tender offer statement by Issuer 171185806
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171185697
  5. 8-K - Current report 171185098
  6. SC TO-I/A [Amend] - Tender offer statement by Issuer 171157920
  7. SC TO-I - Tender offer statement by Issuer 171135638
  8. 8-K - Current report 171135637
  9. 8-K - Current report 171130842
  10. 8-K - Current report 171088282